MOMO Squad

[Let's Roll]

$BKLFF VANCOUVER, BC / ACCESSWIRE / April 20, 2020 / Codebase Ventures Inc. ("Codebase" or the "Company") (CODE.CN)(C5B.F)(BKLLF), an investment company, is pleased to build upon its announcement of April 16th regarding its binding letter of intent to invest in an arms-length private company with rights to a provisional patent for a transdermal drug delivery system for hydroxychloroquine (HCQ), a drug currently used to treat malaria, lupus and rheumatoid arthritis, and being tested as a potential treatment for COVID-19. Hydroxychloroquine is now being tested on a global basis for the treatment and prevention of COVID-19, highlights include:

World Health Organization launches Solidarity clinical trial now in 90 countries on treatment efficacy
UK wide randomized, controlled trial in over 130 hospitals called Recovery is underway
NYU and University of Washington fast track major clinical trial to determine role of HCQ in prevention of coronavirus

Approved by the FDA for malaria, lupus and rheumatoid arthritis, hydroxychloroquine and chloroquine are one of four potential treatments that the World Health Organization has included in its global Solidarity Clinical Trial for COVID-19 Treatments.1 Currently, there are 90 countries participating in Solidarity.

https://seekingalpha.com/pr/17841958-hydroxychloroquine-treatment-for-covidminus-19-benefits-sought-in-global-research-effort-to